Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

WASHINGTON — Robert F. Kennedy Jr. is distancing himself from his anti-vaccine work as he seeks to become the leader of the ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...

UnitedHealth Group (NYSE: UNH) recently reported its Q4 results, with revenues missing and earnings exceeding the street ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.